lpca Laboratories enters into Technology Transfer Agreement with Omexa Formulary
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
The facility will manufacture tablets, capsules, and injections for the oncology segment
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
Operations of Line II was stopped due to a fire incident earlier
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Pharma Solutions operates 10 research and development and/or production sites globally
The MDC business produces components for medical device manufacturers globally with a focus on precious metal alloys and nitinol
Subscribe To Our Newsletter & Stay Updated